IQVIA Holdings Inc. $IQV Shares Sold by Copperleaf Capital LLC

Key Points

• Copperleaf Capital LLC reduced its holdings in IQVIA Holdings Inc. by 42.9%, selling 3,735 shares and now owning 4,969 shares worth approximately $876,000.
• Several institutional investors have increased their positions in IQVIA, with AQR Capital Management boosting its holdings by 58.1%, now owning 675,597 shares valued at $115.87 million.
• IQVIA's share price opened at $184.05, with a reported quarterly earnings of $2.81 EPS, exceeding analyst expectations and reflecting a revenue increase of 5.3% year-over-year.

Copperleaf Capital LLC lessened its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,969 shares of the medical research company's stock after selling 3,735 shares during the quarter. Copperleaf Capital LLC's holdings in IQVIA were worth $876,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Canada Pension Plan Investment Board raised its holdings in IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after purchasing an additional 312,807 shares during the period. JPMorgan Chase & Co. raised its holdings in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after purchasing an additional 798,534 shares during the period. American Century Companies Inc. raised its holdings in IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares during the period. Dimensional Fund Advisors LP raised its holdings in IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after purchasing an additional 40,699 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in IQVIA by 13.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after buying an additional 167,057 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on IQV shares. Redburn Partners set a $214.00 price objective on IQVIA in a research note on Wednesday, September 3rd. Truist Financial boosted their price objective on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. cut their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Barclays boosted their price objective on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, UBS Group boosted their price objective on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $229.86.

IQVIA Trading Up 0.0%

IQV traded up $0.04 during trading hours on Monday, reaching $187.72. The company's stock had a trading volume of 1,304,279 shares, compared to its average volume of 1,920,678. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $248.03. The stock has a market cap of $31.91 billion, a PE ratio of 27.17, a P/E/G ratio of 2.06 and a beta of 1.32. The business's 50-day moving average is $179.88 and its 200-day moving average is $167.23. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the prior year, the firm posted $2.64 earnings per share. The firm's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.